A9522
Anti-Antithrombin III antibody produced in rabbit
fractionated antiserum, lyophilized powder
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
fractionated antiserum
antibody product type
primary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
human
packaging
vial of 2 mL lyophilized antiserum
technique(s)
indirect ELISA: 1:25,000
UniProt accession no.
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... SERPINC1(462)
General description
Antithrombin III (ATIII) is a small glycoprotein produced by the liver that functions as a serine protease inhibitor to block coagulation.
Antithrombin III is a 58kDa glycoprotein synthesized in the liver. It has two domains, a heparin-binding domain and target protease binding domain.
Immunogen
human antithrombin III
Application
Anti-Antithrombin III antibody has been used in western blotting and antigenic assay.
Biochem/physiol Actions
Antithrombin III is a serine protease inhibitor which affects many intrinsic and extrinsic blood coagulation pathways. It inactivates the function of thrombin and factor X in blood. Severe sepsis is caused due to lack of antithrombin III.
Physical form
Lyophilized from 0.01 M phosphate buffered saline, pH 7.2
Preparation Note
Reconstitute with 2 mL deionized water.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Dam. 1
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Maria Eugenia de la Morena-Barrio et al.
Blood, 140(2), 140-151 (2022-04-30)
Antithrombin deficiency, the most severe congenital thrombophilia, might be underestimated, as some pathogenic variants are not detected by routine functional methods. We have identified 2 new SERPINC1 variants, p.Glu227Lys and p.Asn224His, in 4 unrelated thrombophilic patients with early and recurrent
Carlos Bravo-Pérez et al.
American journal of hematology, 97(2), 216-225 (2021-11-21)
Antithrombin deficiency, the most severe thrombophilia, might be underestimated, since it is only investigated in cases with consistent functional deficiency or family history. We have analyzed 444 consecutive, unrelated cases, from 1998 to 2021, with functional results supporting antithrombin deficiency
High-dose antithrombin III in severe sepsis: a randomized controlled trial
Warren B L, et al.
JAMA : The Journal of the American Medical Association, 286(15), 1869-1878 (2001)
Sean P Harrison et al.
Experimental & molecular medicine, 55(9), 2005-2024 (2023-09-01)
The lack of physiological parity between 2D cell culture and in vivo culture has led to the development of more organotypic models, such as organoids. Organoid models have been developed for a number of tissues, including the liver. Current organoid
María E de la Morena-Barrio et al.
American journal of hematology, 96(11), 1363-1373 (2021-07-30)
Atresia of inferior vena cava (IVC) is a rare congenital malformation associated with high risk of venous thrombosis that still has unknown etiology, although intrauterine IVC thrombosis has been suggested to be involved. The identification of IVC atresia in a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service